Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 7/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.45 |
| ▸ | CDK2 | P24941 | 11/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897255 | 1.00 | ADORA3 (0.51) | ADORA3ADORA2AADORA1FLT3CDK1 | |
| SCHEMBL4894170 | 0.86 | FLT3 (0.60) | FLT3CDK1PDGFRACDK2CCNE1 | |
| SCHEMBL4894184 | 0.86 | FLT3 (0.60) | FLT3CDK1PDGFRACDK2CCNE1 | |
| SCHEMBL4899194 | 0.83 | FLT3 (0.48) | FLT3CDK1PDGFRACDK2CCNE1 | |
| SCHEMBL4899218 | 0.83 | FLT3 (0.48) | FLT3CDK1PDGFRACDK2CCNE1 | |
| SCHEMBL5891718 | 0.82 | FLT3 (0.53) | FLT3CDK1PDGFRACDK2CCNE1 | |
| SCHEMBL5891707 | 0.82 | FLT3 (0.53) | FLT3CDK1PDGFRACDK2CCNE1 | |
| SCHEMBL4898746 | 0.82 | FLT3 (0.62) | FLT3CDK1SYKPDGFRACDK2 | |
| SCHEMBL4898733 | 0.82 | FLT3 (0.62) | FLT3CDK1SYKPDGFRACDK2 | |
| SCHEMBL4900930 | 0.81 | FLT3 (0.48) | FLT3CDK1PDGFRACDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | claimed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | claimed |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| EP-1347975-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | Aventis Pharma S.A. (FR) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002051843-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | ADORA3 347/4885ADORA2A 128/4885ADORA1 183/4885 |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | CDK1, CDK6, PNP | ADORA3 335/4885ADORA2A 121/4885ADORA1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.